[1] Janssens R, Struyf S, Proost P. The unique structural and functional features of CXCL12[J].Cell Mol Immunol, 2018, 15(4): 299-311.
[2] Mousavi A. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy[J].Immunol Lett, 2020, 217: 91-115.
[3] Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity[J].Immunity, 2000, 12(2): 121-127.
[4] Busillo JM, Benovic JL. Regulation of CXCR4 signaling[J].Biochim Biophys Acta, 2007, 1768(4): 952-963.
[5] Kawaguchi N, Zhang TT, Nakanishi T. Involvement of CXCR4 in normal and abnormal development[J].Cells, 2019, 8(2): 185.
[6] Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer[J].Clin Cancer Res, 2010, 16(11): 2927-2931.
[7] Wu XX, Zhang HD, Sui ZL, et al. The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma[J].Cancer Biol Med, 2021, 18(2): 401-410.
[8] Zhou WQ, Guo SC, Liu ML, et al. Targeting CXCL12/CXCR4 axis in tumor immunotherapy[J].Curr Med Chem, 2019, 26(17): 3026-3041.
[9] Khare T, Bissonnette M, Khare S. CXCL12-CXCR4/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies[J].Int J Mol Sci, 2021, 22(14): 7371.
[10] 程孟微, 汤郁, 马翠, 等. 同种异体骨髓间充质干细胞输注对MRL/lpr狼疮鼠肾脏CXCL12/CXCR4表达的影响[J].中国组织工程研究, 2022, 26(19): 3018-3023.
[11] 张丹. SDF-1与糖尿病肾病[D].武汉: 华中科技大学, 2012.
[12] Zhang D, Shao SY, Shuai HX, et al. SDF-1α reduces fibronectin expression in rat mesangial cells induced by TGF-β1 and high glucose through PI3K/Akt pathway[J].Exp Cell Res, 2013, 319(12): 1796-1803.
[13] Zhang QZ, He L, Dong Y, et al. Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway[J].FASEB J, 2020, 34(6): 7500-7519.
[14] 林丽. SDF-1/CXCR4在糖尿病肾组织中的表达及其与微血管异常的关系[D].遵义: 遵义医学院, 2010.
[15] 杨志超. 血清淋巴管生成因子VEGF-C、VEGF-D和CXCL-12在糖尿病肾病中表达水平及临床意义[D].南昌: 南昌大学, 2020.
[16] 王昊, 卢明. CXCL12/CXCR4轴的表达和功能研究进展[J].激光生物学报, 2018, 27(2): 97-102.
[17] Darisipudi MN, Kulkarni OP, Sayyed SG, et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease[J].Am J Pathol, 2011, 179(1): 116-124.
[18] Romoli S, Angelotti ML, Antonelli G, et al. CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism[J].Kidney Int, 2018, 94(6): 1111-1126.
[19] 莫红艳. CXCR4介导足细胞损伤及机制研究[D].广州: 南方医科大学, 2018.
[20] Rezvani HR, Ali N, Serrano-Sanchez M, et al. Loss of epidermal hypoxia-inducible factor-1α accelerates epidermal aging and affects re-epithelialization in human and mouse[J].J Cell Sci, 2011, 124(Pt 24): 4172-4183.
[21] Sari S, Cinar S, Yalcinkaya Y, et al. The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus[J].Lupus, 2022, 31(5): 555-564.
[22] Schall N, Daubeuf F, Marsol C, et al. A selective neutraligand for CXCL12/SDF-1α with beneficial regulatory functions in MRL/lpr lupus prone mice[J].Front Pharmacol, 2021, 12: 752194.
[23] Wang A, Fairhurst AM, Tus K, et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus[J].J Immunol, 2009, 182(7): 4448-4458.
[24] Badr G, Sayed A, Abdel-Maksoud MA, et al. Infection of female BWF1 lupus mice with malaria parasite attenuates B cell autoreactivity by modulating the CXCL12/CXCR4 axis and its downstream signals PI3K/AKT, NFκB and ERK[J].PLoS One, 2015, 10(4): e0125340.
[25] Zeng QQ, Sun SL, Li YX, et al. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in the renal cell carcinoma microenvironment[J].Front Oncol, 2020, 9: 1555.
[26] Liu J, Lu XH, Lou Y, et al. Xenogeneic transplantation of human placenta-derived mesenchymal stem cells alleviates renal injury and reduces inflammation in a mouse model of lupus nephritis[J].Biomed Res Int, 2019, 2019: 9370919.
[27] Devarapu SK, Kumar VR S, Rupanagudi KV, et al. Reprint of dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis[J].Clin Immunol, 2017, 185: 119-127.
[28] Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J].Nature, 2001, 410(6824): 50-56.
[29] Floranovia MP, Veliakovia LJ. Effect of CXCL12 and its receptors on unpredictable renal cell carcinoma[J].Clin Genitourin Cancer, 2020, 18(4): e337-e342.
[30] Poti? Floranovi? M, Risti? Petrovi? A, Veli?kovia F, et al. Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma[J].Clin Exp Nephrol, 2021, 25(10): 1057-1069.
[31] 郝天春. HIF-1α和CXCR4在肾透明细胞癌中的表达及意义[D].合肥: 安徽医科大学, 2010.
[32] Oh SI, Jeong H, Park HS, et al. Activation of CXCL12-CXCR4 signalling induces conversion of immortalised embryonic kidney cells into cancer stem-like cells[J].Artif Cells Nanomed Biotechnol, 2020, 48(1): 1303-1313.
[33] Yu P, Liu JX, Zhang Y, et al. The post-transcriptional inhibition of CXCR4 expression by miR-139 regulates the proliferation of human kidney cancer cells[J].Acta Biochim Pol, 2022, 69(1): 189-195.
[34] Pan JD, Mestas J, Burdick MD, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis[J].Mol Cancer, 2006, 5: 56.
[35] Bao Y, Wang ZX, Liu B, et al. A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis[J].Oncogene, 2019, 38(6): 881-895.
[36] Santagata S, Napolitano M, D'Alterio C, et al. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer[J].Oncotarget, 2017, 8(44): 77110-77120.
[37] Neusser MA, Kraus AK, Regele H, et al. The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection[J].Kidney Int, 2010, 77(9): 801-808.
[38] 唐浩,徐岳,曾嵩,等. SDF-1/CXCR4信号通路在大鼠移植肾慢性排斥反应中的作用及其机制研究[J].中华器官移植杂志, 2017, 38(6): 365-371.
[39] 王思微, 牛广华. CXCL12、CXCR4与IL-6在特发性膜性肾病中的表达及临床意义[J].国际检验医学杂志, 2021, 42(5): 513-516, 520.
